Export 5643 results:
Sort by: [ Author  (Desc)] Title Type Year
A B C D E F G H I J [K] L M N O P Q R S T U V W X Y Z   [Show ALL]
KZ, F., and E. L. MH, "6. Contiuous versus pulsed ultrasound on myofascial pain syndrome: Randomized single blind controlled trial", International journal of Therapies and Rehabilitation research, vol. 6, issue 2, pp. 75-81, 2017.
Kyyaly, M. A., A. S. Zaky, and C. D. Powell, "Production of Baker's yeast using seawater-based media.", New Biotechnology, vol. 33, issue S71, 2016. Abstract
Kyu, H. H., D. Abate, K. H. Abate, S. M. Abay, C. Abbafati, N. Abbasi, H. Abbastabar, F. Abd-Allah, J. Abdela, and A. Abdelalim, "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017", The Lancet, vol. 392, issue 10159: Elsevier, pp. 1859-1922, 2018. Abstract
Kyrou, D., H. M. Fatemi, P. Devroey, G. E. P. Neto, G. S. Moraes, R. A. Cristovam, H. E. Corleta, B. A. Lessey, R. F. Savaris, A. M. Abou-Setta, et al., "Session 31: Ovarian Stimulation 1", Human Reproduction, vol. 25, 2010. Abstract
Kyriakopoulou, K., E. Riti, Z. Piperigkou, K. Koutroumanou Sarri, H. Bassiony, M. Franchi, and N. K. Karamanos, "ΕGFR/ERβ-Mediated Cell Morphology and Invasion Capacity Are Associated with Matrix Culture Substrates in Breast Cancer.", Cells, vol. 9, issue 10, 2020. Abstract

Breast cancer accounts for almost one in four cancer diagnoses in women. Studies in breast cancer patients have identified several molecular markers, indicators of aggressiveness, which help toward more individual therapeutic approaches. In triple-negative breast cancer (TNBC), epidermal growth factor receptor (EGFR) overexpression is associated with increased metastatic potential and worst survival rates. Specifically, abnormal EGFR activation leads to altered matrix metalloproteinases' (MMPs) expression and, hence, extracellular matrix (ECM) degradation, resulting in induced migration and invasion. The use of matrix substrates for cell culture gives the opportunity to mimic the natural growth conditions of the cells and their microenvironment, as well as cell-cell and cell-matrix interactions. The aim of this study was to evaluate the impact of EGFR inhibition, estrogen receptor beta (ERβ) and different matrix substrates [type I collagen and fibronectin (FN)] on the functional properties, expression of MMPs and cell morphology of ERβ-positive TNBC cells and shERβ ones. Our results highlight EGFR as a crucial regulator of the expression and activity levels of MMPs, while ERβ emerges as a mediator of MMP7 and MT1-MMP expression. In addition, the EGFR/ERβ axis impacts the adhesion and invasion potential of breast cancer cells on collagen type I. Images obtained by scanning electron microscope (SEM) from cultures on the different matrix substrates revealed novel observations regarding various structures of breast cancer cells (filopodia, extravesicles, tunneling nanotubes, etc.). Moreover, the significant contribution of EGFR and ERβ in the morphological characteristics of these cells is also demonstrated, hence highlighting the possibility of dual pharmacological targeting.

Kyriakopoulou, K., E. Kefali, Z. Piperigkou, H. Bassiony, and N. K. Karamanos, "Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer.", Cellular signalling, vol. 51, pp. 99-109, 2018. Abstract

Breast cancer is the most common malignancy among women worldwide. The role of epidermal growth factor receptor (EGFR) in many epithelial malignancies has been established, since it is dysregulated, overexpressed or mutated. Its overexpression has been associated with increased aggressiveness and metastatic potential in breast cancer. The well-established interplay between EGFR signaling pathway and estrogen receptors (ERs) as well as major extracellular matrix (ECM) mediators is crucial for regulating basic functional properties of breast cancer cells, including migration, proliferation, adhesion and invasion. EGFR activation leads to endocytosis of the receptor with implications in the regulation of downstream signaling effectors, the modulation of autophagy and cell survival. Therefore, EGFR is considered as a promising therapeutic target in breast cancer. Several anti-EGFR therapies (i.e. monoclonal antibodies and tyrosine kinase inhibitors) have been evaluated both in vitro and in vivo, making their way to clinical trials. However, the response rates of anti-EGFR therapies in the clinical trials is low mainly due to chemoresistance. Novel drug design, phytochemicals and microRNAs (miRNAs) are assessed as new therapeutic approaches against EGFR. The main goal of this review is to highlight the importance of targeting EGFR signaling pathway in terms of its crosstalk with ERs, the involvement of ECM effectors and epigenetics. Moreover, recent insights into the design of specialized delivery systems contributing in the development of novel diagnostic and therapeutic approaches in breast cancer are addressed.

KY El-Nagmy, MRM Ibrahim, M. O. A. - E., "Effect of dietary protein and total sulfr amino acid levels on performance, nutrient digestibility and carcass traits of growing crossbred rabbits.", The 3rd Conference of the Egyptian Rabbit Science Association, 8 – 11 October, 2002, Hurghada, Egypt., 2002. Abstract
Kwinn, L. A., A. Khosravi, R. K. Aziz, A. M. Timmer, K. S. Doran, M. Kotb, and V. Nizet, "Genetic characterization and virulence role of the RALP3/LSA locus upstream of the streptolysin S operon in invasive M1T1 group A Streptococcus", Journal of bacteriology, vol. 189, no. 4: American Society for Microbiology, pp. 1322–1329, 2007. Abstract
Kwiecien, G. J., S. Rueda, R. A. Couto, A. Hashem, S. Nagel, G. S. Schwarz, J. E. Zins, and B. R. Gastman, "Long-term Outcomes of Cranioplasty: Titanium Mesh Is Not a Long-term Solution in High-risk Patients.", Annals of plastic surgery, vol. 81, issue 4, pp. 416-422, 2018 Oct. Abstract

BACKGROUND: Titanium mesh is a popular material for cranioplasty. However, long-term outcomes of these reconstructions remain unknown. We aimed to compare long-term outcomes between patients undergoing both (1) skull reconstruction with titanium mesh and other commonly used cranioplasty materials and (2) scalp reconstructions with locoregional flaps and free tissue transfers.

METHODS: A retrospective review of patients treated with 466 cranioplasties (401 patients) between 2002 and 2014 was performed.

RESULTS: Materials used for reconstructions included nontitanium alloplast (52.0%), titanium mesh (38%), and autologous bone (10%). Median cranial defect size was 58.4 cm. Eighty-three reconstructions (18%) included full-thickness scalp defect with a median area of 155.4 cm. Median follow-up was 3.9 years. Retention rate for isolated cranioplasty was 90%, 89.9%, and 77.1% for titanium mesh, nontitanium alloplast, and autologous bone, respectively (P > 0.05). In composite defect cases, retention rate for autologous bone was comparable, 81.8% (P > 0.05), whereas for titanium mesh and nontitanium alloplast it was significantly lower, 46.8% and 72.0%, respectively (P < 0.05). The retention rate of titanium mesh cranioplasty with free fascio- and myocutaneous flaps was higher when compared with locoregional and free muscle flaps (P < 0.05).

CONCLUSIONS: Titanium mesh offers a durable repair of isolated bone defects. However, in high-risk patients with soft-tissue defect, the outcomes are significantly worse. In these cases, free tissue transfer for soft-tissue coverage tends to be more successful, especially when using a myocutaneous or fasciocutaneous free flap. This is the first study to identify a high complication rate of this popular material, especially when it is combined with a locoregional scalp flap or free muscle flap. Therefore, in these cases, titanium mesh should be used with caution.

Kwiatkowski, J. L., M. O. N. A. HAMDY, A. El-Beshlawy, F. S. Ebeid, M. Badr, A. Alshehri, J. Kanter, B. Inusa, A. A. M. Adly, S. Williams, et al., "Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.", Blood advances, vol. 6, issue 4, pp. 1243-1254, 2022. Abstract

Many people with sickle cell disease (SCD) or other anemias require chronic blood transfusions, which often causes iron overload that requires chelation therapy. The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited. This open-label study assessed the efficacy and safety of deferiprone in patients with SCD or other anemias receiving chronic transfusion therapy. A total of 228 patients (mean age: 16.9 [range, 3-59] years; 46.9% female) were randomized to receive either oral deferiprone (n = 152) or subcutaneous deferoxamine (n = 76). The primary endpoint was change from baseline at 12 months in liver iron concentration (LIC), assessed by R2* magnetic resonance imaging (MRI). The least squares mean (standard error) change in LIC was -4.04 (0.48) mg/g dry weight for deferiprone vs -4.45 (0.57) mg/g dry weight for deferoxamine, with noninferiority of deferiprone to deferoxamine demonstrated by analysis of covariance (least squares mean difference 0.40 [0.56]; 96.01% confidence interval, -0.76 to 1.57). Noninferiority of deferiprone was also shown for both cardiac T2* MRI and serum ferritin. Rates of overall adverse events (AEs), treatment-related AEs, serious AEs, and AEs leading to withdrawal did not differ significantly between the groups. AEs related to deferiprone treatment included abdominal pain (17.1% of patients), vomiting (14.5%), pyrexia (9.2%), increased alanine transferase (9.2%) and aspartate transferase levels (9.2%), neutropenia (2.6%), and agranulocytosis (0.7%). The efficacy and safety profiles of deferiprone were acceptable and consistent with those seen in patients with transfusion-dependent thalassemia. This trial study was registered at www:// as #NCT02041299.

Kwan, J. M., Z. Hajjiri, Y. F. Chen, A. Metwally, D. L. Perkins, and P. W. Finn, "Donor and Recipient Ethnicity Impacts Renal Graft Adverse Outcomes", Journal of racial and ethnic health disparities, vol. 5, no. 5: Springer International Publishing, pp. 1003–1013, 2018. Abstract
Kwan, J. M., Z. Hajjiri, A. Metwally, P. W. Finn, and D. L. Perkins, "Effect of the obesity epidemic on kidney transplantation: obesity is independent of diabetes as a risk factor for adverse renal transplant outcomes", PloS one, vol. 11, no. 11: Public Library of Science, pp. e0165712, 2016. Abstract
Kwak, Y., S. Nam, M. Akçakaya, T. A. Basha, B. Goddu, W. J. Manning, V. Tarokh, and R. Nezafat, "Accelerated aortic flow assessment with compressed sensing with and without use of the sparsity of the complex difference image", Magnetic resonance in medicine, vol. 70, issue 3, pp. 851-858, 2013. Abstract
Kwak, Y., S. Nam, M. Akçakaya, T. A. Basha, B. Goddu, W. J. Manning, V. Tarokh, and R. Nezafat, "Accelerated aortic flow assessment with compressed sensing with and without use of the sparsity of the complex difference image", Magnetic resonance in medicine, vol. 70, no. 3, pp. 851–858, 2013. Abstract
Kuznetsov, V. A., M. Szulik, T. M. Katova, M. P. P. Michalis, C. H. A. Jost, M. S. V. Del Castillo, Y. Y. Lam, A. Mazzone, S. Herrmann, Z. Y. Yong, et al., "", European Heart Journal-Cardiovascular Imaging, vol. 11, no. suppl 2: The Oxford University Press, pp. ii12–ii41, 2010. Abstract
Kuznetsov, V. A., M. Szulik, T. M. Katova, M. P. P. Michalis, C. H. A. Jost, M. S. V. Del Castillo, Y. Y. Lam, A. Mazzone, S. Herrmann, Z. Y. Yong, et al., "", European Heart Journal-Cardiovascular Imaging, vol. 11, no. suppl 2: The Oxford University Press, pp. ii12–ii41, 2010. Abstract
Kutlar, A., M. E. Reid, A. Inati, A. T. Taher, M. R. Abboud, A. El-Beshlawy, G. R. Buchanan, H. Smith, K. I. Ataga, S. P. Perrine, et al., "A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.", American journal of hematology, vol. 88, issue 11, pp. E255-60, 2013 Nov. Abstract

2,2-Dimethylbutyrate (HQK-1001), an orally-bioavailable promoter-targeted fetal globin gene-inducing agent, was evaluated in an open-label, randomized dose-escalation study in 52 subjects with hemoglobin SS or S/β(0) thalassemia. HQK-1001 was administered daily for 26 weeks at 30 mg/kg (n = 15), 40 mg/kg (n = 18) and 50 mg/kg (n = 19), either alone (n = 21) or with hydroxyurea (n = 31). The most common drug-related adverse events were usually mild or moderate and reversible. Gastritis was graded as severe in three subjects at 40 mg/kg and was considered the dose-limiting toxicity. Subsequently all subjects were switched to the maximum tolerated dose of 30 mg/kg. Due to early discontinuations for blood transfusions, adverse events or non-compliance, only 25 subjects (48%) completed the study. Drug plasma concentrations were sustained above targeted levels at 30 mg/kg. Increases in fetal hemoglobin (Hb F) were observed in 42 subjects (80%), and 12 (23%) had increases ≥4%. The mean increase in Hb F was 2% [95% confidence interval (CI), 0.8-3.2%] in 21 subjects receiving HQK-1001 alone and 2.7% (95% CI, 1.7-3.8%) in 31 subjects receiving HQK-1001 plus hydroxyurea. Total hemoglobin increased by a mean of 0.65 g/dL (95% CI, 0.5-1.0 g/dL), and 13 subjects (25%) had increases ≥1 g/dL. Future studies are warranted to evaluate the therapeutic potential of HQK-1001 in sickle cell disease. .

kutkat, M. A., R. M. Shalaby, R. M. El Khateeb, N. M. Abu Elezz, A. A. Zayed, A. B. Abd El-Razik, S. A. Nassif, and M. Amer, "Molecular diagnosis of Eimeria and Clostridia in simultaneously infected chickens. ", Global Veterinaria , vol. 3, issue 1, pp. 26-31, 2009. molecular_diagnosis_of_eimeria_and_clostridia.pdf
Kursat Bozkurt, Eberhard Rabe, and M. I. Sharkawy, "Chronic Venous Insufficiency: Management and Treatment", EMJ Dermatol, vol. 5, issue Suppl 2, pp. 2-13, 2017. chronic-venous-insufficiency.pdf
Kurdi, A. S., and M. Y. Amin, "“Identification of spectral lines of alpha Cen A star : possibly at spot maximum”", Journal of the Astronomical Society of Egypt., vol. 11, pp. 1-18, 2003.
Kurdi, A. S., and M. Y. Amin, ". “Zeeman Splitting of CrI 6881.715 A0, ScII 6882.520 A0 and CrI 6883.070 A0 lines in alpha Cen A “ ", New Astronomy, vol. 9/7, pp. 537-543, 2004.
Kurdi, A. - S., and M. Y. Amin, "تحقيق وشرح رسالة أبن الشاطر في علم الإسطرلاب"", مجلة جامعة أم القرى , 2001.
Kuramoto, H., and M. Shimazu, "Control of house fly populations by Entomophthora muscae (Zygomycotina: Entomophthorales) in a poultry house", Applied entomology and zoology, vol. 32, issue 2: Japanese Society of Applied Entomology and Zoology, pp. 325-331, 1997. Abstract
Kuraidi, A. A. -, "نظرة جديدة إلي التواصل الثقافي والعولمة- تأثير الآخر علي الأنا ممثلاً هذه المرة فى تأثير الشرق الأقصي علي الشرق الأوسط نموذجاً", Arab Journal for Scientific Publishing "ISSN: 2663-5798", vol. 11, 2019. AbstractWebsite

Here I capture the appearance of "Arab Haiku" as a result of cultural exchange with The Other (of Asia, this time).
Here, it`s clear where it succeeded and where it failed. Reasons for such success and failure, stated by critics and other professionals, are included as well. The majority who threw away "The Self", "The Old" and "The Modern" and replaced them with their newest "strange mixture" (literary trend) failed, while the minority who kept characteristics of "The Self" creating its harmonic coexistence with The Other, applying peaceful coexistence of the old, the modern and "the good" newest succeeded. (This is similar to Japan`s postwar case, where mentioned peaceful coexistence helped it achieving its ultra-fast development).
Finally, I admit necessity of cultural exchange and prove possibility of cultural coexistence and interaction (even in cultural exchange cases that are considered impossible) provided that correct exchange methods and rules are used.

Kuraidi, A. A. -, "التغير الحتمي للنص المترجم والحفاظ على المعنى في ظل ذلك-الترجمة الاسلامية نموذجاً", Arab Journal for Scientific Publishing "ISSN: 2663-5798", vol. 14, pp. 124-153, 2019.